ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 161 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2017. The put-call ratio across all filers is 0.31 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,703,073 | +113287.0% | 36,919 | -1.5% | 0.02% | -13.0% |
| Q1 2023 | $1,502 | -99.9% | 37,467 | +4.9% | 0.02% | -28.1% |
| Q3 2022 | $1,480,000 | +51.3% | 35,729 | +118.0% | 0.03% | +23.1% |
| Q2 2022 | $978,000 | +162.2% | 16,391 | +270.0% | 0.03% | +333.3% |
| Q4 2021 | $373,000 | -88.4% | 4,430 | -87.6% | 0.01% | -88.5% |
| Q3 2021 | $3,228,000 | +113.5% | 35,789 | +125.7% | 0.05% | +79.3% |
| Q2 2021 | $1,512,000 | -38.3% | 15,857 | -10.5% | 0.03% | -58.0% |
| Q4 2020 | $2,452,000 | +86.6% | 17,712 | +10.8% | 0.07% | +21.1% |
| Q3 2020 | $1,314,000 | +57.6% | 15,985 | +49.9% | 0.06% | +39.0% |
| Q2 2020 | $834,000 | +37.2% | 10,667 | -25.0% | 0.04% | +95.2% |
| Q3 2019 | $608,000 | +41.4% | 14,214 | +124.1% | 0.02% | +61.5% |
| Q1 2017 | $430,000 | +83.0% | 6,343 | +159.9% | 0.01% | +62.5% |
| Q3 2015 | $235,000 | – | 2,441 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iguana Healthcare Management, LLC | 75,000 | $5,084,000 | 2.52% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 1,237,825 | $83,900,000 | 1.18% |
| CAPITAL INTERNATIONAL LTD /CA/ | 206,718 | $14,011,000 | 0.91% |
| Cormorant Asset Management, LP | 75,000 | $5,084,000 | 0.74% |
| Capital International Sarl | 107,450 | $7,283,000 | 0.63% |
| Rock Springs Capital Management LP | 159,750 | $10,828,000 | 0.62% |
| Opus Point Partners Management, LLC | 12,201 | $827,000 | 0.61% |
| Hood River Capital Management LLC | 109,629 | $7,431,000 | 0.56% |
| Aureus Asset Management, LLC | 50,740 | $2,927,000 | 0.51% |
| ROCKEFELLER FINANCIAL SERVICES INC | 374,663 | $25,395,000 | 0.51% |